Skip to main content
Premium Trial:

Request an Annual Quote

PathoGenetix Raises $4M in First Close of Series B

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PathoGenetix, formerly called US Genomics, announced today the first closing of its Series B financing round, raising $4 million.

The Woburn, Mass.-based company added that it has received $9.5 million in commitments from investors for the round.

The funds will be used to complete development of PathoGenetix's first commercial systems for identifying pathogens in complex biological samples using its Genome Sequence Scanning technology.

The funding, said John Canepa, CEO of PathoGenetix, will allow the company to "enter the rapidly growing research market for microbiome analysis, and advance the development of applications for food and product safety and clinical diagnostics."

The Genome Sequence Scanning technology was initially developed with more than $50 million from the US Department of Defense and the US Department of Homeland Security under their advanced biosensor programs.

The technology "extracts genomic barcodes from microbial DNA as it flows through a microfluidic chip at 150 million base pairs per second," PathoGenetix said in a statement. It added that complex clinical specimens can be scanned to identify thousands of pathogenic strains in less time and more inexpensively than with current technologies.

According to PathoGenetix, potential applications for the technology include the acceleration of disease diagnosis and improvement of antibiotic treatment; streamlining of clinical trials; and reduction of time for the detection and source tracking of life-threatening food-borne pathogens from weeks to hours.

Investors included Excel Venture Management, which led the round, CB Health Ventures, HealthCare Ventures, and others who also participated in PathoGenetix's Series A round in late 2010.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.